BOUNDLESS BIO INC Financials
This page shows BOUNDLESS BIO INC (BOLD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BOUNDLESS BIO INC passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BOUNDLESS BIO INC generates $0.93 in operating cash flow (-$60.8M OCF vs -$65.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
BOUNDLESS BIO INC's EBITDA was -$72.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.1% from the prior year.
BOUNDLESS BIO INC generated -$63.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 33.5% from the prior year.
BOUNDLESS BIO INC reported -$65.4M in net income in fiscal year 2024. This represents a decrease of 32.2% from the prior year.
BOUNDLESS BIO INC earned $-3.85 per diluted share (EPS) in fiscal year 2024. This represents an increase of 90.5% from the prior year.
BOUNDLESS BIO INC held $26.6M in cash against $0 in long-term debt as of fiscal year 2024.
BOUNDLESS BIO INC had 22M shares outstanding in fiscal year 2024. This represents an increase of 1786759.0% from the prior year.
BOUNDLESS BIO INC invested $55.3M in research and development in fiscal year 2024. This represents an increase of 29.6% from the prior year.
BOUNDLESS BIO INC invested $2.5M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 300.6% from the prior year.
BOLD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $10.7M-12.6% | $12.2M+0.7% | $12.1M-13.8% | $14.1M-4.4% | $14.7M+12.2% | $13.1M | N/A | $11.6M |
| SG&A Expenses | $4.5M-7.6% | $4.8M-6.9% | $5.2M+12.5% | $4.6M-0.6% | $4.7M+24.0% | $3.8M | N/A | $3.3M |
| Operating Income | -$15.1M+11.2% | -$17.1M+1.6% | -$17.3M+7.3% | -$18.7M+3.5% | -$19.4M-14.9% | -$16.9M | N/A | -$15.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$13.9M+11.5% | -$15.7M+0.5% | -$15.8M+4.5% | -$16.5M+2.8% | -$17.0M-10.0% | -$15.4M | N/A | -$13.2M |
| EPS (Diluted) | $-0.62+11.4% | $-0.70+1.4% | $-0.71+4.1% | $-0.74+3.9% | $-0.77+93.7% | $-12.27 | N/A | $-10.71 |
BOLD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $168.7M-6.0% | $179.5M-6.2% | $191.2M-7.3% | $206.4M+9.7% | $188.2M+60.8% | $117.1M-9.9% | $129.9M | N/A |
| Current Assets | $120.2M-7.4% | $129.7M-7.6% | $140.4M-9.1% | $154.4M-15.7% | $183.1M+63.3% | $112.2M-9.7% | $124.2M | N/A |
| Cash & Equivalents | $15.0M+1.9% | $14.7M-2.8% | $15.1M-43.1% | $26.6M-15.2% | $31.4M+24.7% | $25.1M+6.1% | $23.7M+13.1% | $21.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $58.6M+3.2% | $56.8M+3.9% | $54.6M-2.0% | $55.8M+522.6% | $9.0M-96.5% | $258.3M+0.5% | $257.0M | N/A |
| Current Liabilities | $11.8M+28.6% | $9.2M+45.4% | $6.3M-22.1% | $8.1M-9.2% | $9.0M-15.8% | $10.6M+13.7% | $9.4M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $110.2M-10.2% | $122.7M-10.2% | $136.6M-9.3% | $150.6M-16.0% | $179.2M+227.0% | -$141.2M-11.1% | -$127.1M-9.5% | -$116.0M |
| Retained Earnings | -$246.8M-6.0% | -$232.9M-7.2% | -$217.2M-7.8% | -$201.5M-19.6% | -$168.5M-11.2% | -$151.5M-11.3% | -$136.1M | N/A |
BOLD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M+13.8% | -$11.8M+18.6% | -$14.5M+6.6% | -$15.6M+4.1% | -$16.2M-2.9% | -$15.8M-35.0% | -$11.7M+4.1% | -$12.2M |
| Capital Expenditures | $15K-68.8% | $48K-18.6% | $59K-87.3% | $466K-69.0% | $1.5M+1712.0% | $83K-69.0% | $268K+77.5% | $151K |
| Free Cash Flow | -$10.2M+14.0% | -$11.9M+18.6% | -$14.6M+9.0% | -$16.0M+9.6% | -$17.7M-11.9% | -$15.9M-32.7% | -$12.0M+3.1% | -$12.3M |
| Investing Cash Flow | $10.5M-7.2% | $11.3M+269.0% | $3.1M+67.9% | $1.8M+102.7% | -$68.2M-476.0% | $18.1M+14.7% | $15.8M+304.9% | -$7.7M |
| Financing Cash Flow | $0 | N/A | N/A | $113K-99.9% | $90.6M+9910.3% | -$924K+33.2% | -$1.4M-209.6% | -$447K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BOLD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.2%+0.5pp | -8.7%-0.5pp | -8.2%+1.2pp | -9.4%-0.4pp | -9.0%+4.2pp | -13.2% | N/A | N/A |
| Current Ratio | 10.14-3.9 | 14.08-8.1 | 22.15+3.2 | 18.98-1.5 | 20.45+9.9 | 10.54-2.7 | 13.27 | N/A |
| Debt-to-Equity | 0.53+0.1 | 0.46+0.1 | 0.40+0.0 | 0.37+0.3 | 0.05+1.9 | -1.83+0.2 | -2.02 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is BOUNDLESS BIO INC profitable?
No, BOUNDLESS BIO INC (BOLD) reported a net income of -$65.4M in fiscal year 2024.
What is BOUNDLESS BIO INC's earnings per share (EPS)?
BOUNDLESS BIO INC (BOLD) reported diluted earnings per share of $-3.85 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is BOUNDLESS BIO INC's EBITDA?
BOUNDLESS BIO INC (BOLD) had EBITDA of -$72.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is BOUNDLESS BIO INC's free cash flow?
BOUNDLESS BIO INC (BOLD) generated -$63.4M in free cash flow during fiscal year 2024. This represents a -33.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BOUNDLESS BIO INC's operating cash flow?
BOUNDLESS BIO INC (BOLD) generated -$60.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are BOUNDLESS BIO INC's total assets?
BOUNDLESS BIO INC (BOLD) had $206.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are BOUNDLESS BIO INC's capital expenditures?
BOUNDLESS BIO INC (BOLD) invested $2.5M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does BOUNDLESS BIO INC spend on research and development?
BOUNDLESS BIO INC (BOLD) invested $55.3M in research and development during fiscal year 2024.
How many shares does BOUNDLESS BIO INC have outstanding?
BOUNDLESS BIO INC (BOLD) had 22M shares outstanding as of fiscal year 2024.
What is BOUNDLESS BIO INC's current ratio?
BOUNDLESS BIO INC (BOLD) had a current ratio of 18.98 as of fiscal year 2024, which is generally considered healthy.
What is BOUNDLESS BIO INC's debt-to-equity ratio?
BOUNDLESS BIO INC (BOLD) had a debt-to-equity ratio of 0.37 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BOUNDLESS BIO INC's return on assets (ROA)?
BOUNDLESS BIO INC (BOLD) had a return on assets of -31.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is BOUNDLESS BIO INC's cash runway?
Based on fiscal year 2024 data, BOUNDLESS BIO INC (BOLD) had $26.6M in cash against an annual operating cash burn of $60.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is BOUNDLESS BIO INC's Piotroski F-Score?
BOUNDLESS BIO INC (BOLD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BOUNDLESS BIO INC's earnings high quality?
BOUNDLESS BIO INC (BOLD) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.